Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU
Nivolumab plus ipilimumab showed superior overall survival versus standard-of-care chemotherapy in patients with unresectable malignant mesothelioma.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Asbestosis | Cancer & Oncology | Chemotherapy | Hematology | Immunotherapy | Mesothelioma | Yervoy